Wegovy® is now available as a once-daily pill — and that changes the conversation around obesity treatment, cardiovascular risk reduction, access, and adherence.

In this week’s Refill, we revisit our original GLP-1 deep dive and add the latest updates:

✔️ FDA approval details ✔️ Oral vs injection dosing ✔️ Clinical trial data ✔️ Cost comparisons ✔️ Side effects ✔️ Who this impacts most

Same episode. New context. Because medicine doesn’t stand still.

🎙️ Listen wherever you get your podcasts. ⭐ Rate, review & follow — new episodes drop Mondays.

#MedicalMediaMixer #GLP1 #Wegovy #ObesityMedicine #CardiovascularHealth #RefillEpisode #Semaglutide

1. FDA Orange Book. 2026.
2. Wegovy® (semaglutide) FDA Drug Label. Updated December 22, 2025.
3. Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025.
4. Rubino D, Abrahamsson N, Davies M, et al. STEP 4 Trial. JAMA. 2021.
5. Ryan DH, Lingvay I, Deanfield J, et al. SELECT Trial. Nature Medicine. 2024.
6. Schweitzer K. What to Know About the Wegovy Pill for Obesity. JAMA. 2026.
7. AACE Consensus Statement 2025 Update. Endocrine Practice.

New episodes every Monday → Hit that subscribe button! 🔔

⭐️ Rate and Review

🍸 Cocktail recipes drop on socials every weekend before the episode airs 🍹

If you love the podcast, please join our 💳 Patreon to support our continued success!

If you don't want to commit to a monthly contribution, you can always donate on ☕️Buy Me a Coffee

🎶 Music Credits: Music by Vlad Krotov, Sound Effect by Akiva Vita For updates visit our 💻 Website